<DOC>
	<DOCNO>NCT00889226</DOCNO>
	<brief_summary>A randomized , open label , dose titration study evaluate efficacy safety Pitavastatin compare atorvastatin Type 2 Diabetes Mellitus hypercholesterolemia</brief_summary>
	<brief_title>Efficacy Safety Study Pitavastatin Compared atoRvastatin Type 2 dIabeTes Mellitus With Hypercholesterolemia</brief_title>
	<detailed_description>To evaluate effect pitavastatin compare atorvastatin change Lipid profile , ApoA1 , ApoB , adiponectin baPWV marker atherosclerosis Type 2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Age : 25yrs~75yrs Fasting TG &lt; 400mg/dL , LDLC ≥130mg/dL 3months &gt; Diagnosed Type2 DM , With OAD , HbA1c ≤ 10.0 % First Diagnosed Type2 DM , 6.5 % ≤HbA1c≤10.0 % Type1 DM , Gestational diabetes Patient need treat Insulin Patient operational treatment severe diabetic complication Uncontrolled Hypothyroidism Unstable angina , MI , transient ischemic attack ( TIA ) , Stroke , PCI , Heart Failure within 3 month ( NYHA class4 ) Severe Hypertension ( SBP ≥ 180 DBP ≥ 110mmHg ) Renal disorder ( Serum creatinine ≥ 2.0mg/dL ) Hepatic disorder ( AST ALT ≥ 2.5 X UNL ) Creatinine Kinase &gt; 2.5 X UNL Gravida lactation phase Administration Atorvastatin , Rosuvastatin , Pitavastatin</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>pitavastatin</keyword>
	<keyword>PWV</keyword>
	<keyword>ESPRIT</keyword>
	<keyword>Pitavastatin Atorvastatin</keyword>
	<keyword>Adiponectin</keyword>
	<keyword>fast insulin</keyword>
	<keyword>hs-CRP</keyword>
	<keyword>baPWV</keyword>
</DOC>